runners.py:266 WARNING: App name mismatch detected. The runner is configured with app name "InMemoryRunner", but the root agent was loaded from "D:\Google Course\myenv\Lib\site-packages\google\adk\agents", which implies app name "agents".
google_llm.py:133 INFO: Sending out request, model: gemini-2.5-flash-lite, backend: GoogleLLMVariant.GEMINI_API, stream: False
google_llm.py:139 DEBUG: 
LLM Request:
-----------------------------------------------------------
System Instruction:
Your task is to find research papers and count them. 

    You MUST ALWAYS follow these steps:
    1) Find research papers on the user provided topic using the 'google_search_agent'. 
    2) Then, pass the papers to 'count_papers' tool to count the number of papers returned.
    3) Return both the list of research papers and the total number of papers.

You are an agent. Your internal name is "root_agent".
-----------------------------------------------------------
Config:
{'tools': [{}]}
-----------------------------------------------------------
Contents:
{"parts":[{"text":"what are the research on alopecia areta?"}],"role":"user"}
-----------------------------------------------------------
Functions:
paper_count: {'papers': {'type': <Type.STRING: 'STRING'>}} 
google_search_agent: {'request': {'type': <Type.STRING: 'STRING'>}} 
-----------------------------------------------------------

_trace.py:87 DEBUG: connect_tcp.started host='generativelanguage.googleapis.com' port=443 local_address=None timeout=None socket_options=None
_trace.py:87 DEBUG: connect_tcp.complete return_value=<httpcore._backends.anyio.AnyIOStream object at 0x0000022B3CBC9010>
_trace.py:87 DEBUG: start_tls.started ssl_context=<ssl.SSLContext object at 0x0000022B3C7BF4A0> server_hostname='generativelanguage.googleapis.com' timeout=None
_trace.py:87 DEBUG: start_tls.complete return_value=<httpcore._backends.anyio.AnyIOStream object at 0x0000022B3CBADA90>
_trace.py:87 DEBUG: send_request_headers.started request=<Request [b'POST']>
_trace.py:87 DEBUG: send_request_headers.complete
_trace.py:87 DEBUG: send_request_body.started request=<Request [b'POST']>
_trace.py:87 DEBUG: send_request_body.complete
_trace.py:87 DEBUG: receive_response_headers.started request=<Request [b'POST']>
_trace.py:87 DEBUG: receive_response_headers.complete return_value=(b'HTTP/1.1', 200, b'OK', [(b'Content-Type', b'application/json; charset=UTF-8'), (b'Vary', b'Origin'), (b'Vary', b'X-Origin'), (b'Vary', b'Referer'), (b'Content-Encoding', b'gzip'), (b'Date', b'Wed, 19 Nov 2025 11:39:24 GMT'), (b'Server', b'scaffolding on HTTPServer2'), (b'X-XSS-Protection', b'0'), (b'X-Frame-Options', b'SAMEORIGIN'), (b'X-Content-Type-Options', b'nosniff'), (b'Server-Timing', b'gfet4t7; dur=1031'), (b'Alt-Svc', b'h3=":443"; ma=2592000,h3-29=":443"; ma=2592000'), (b'Transfer-Encoding', b'chunked')])
_client.py:1740 INFO: HTTP Request: POST https://generativelanguage.googleapis.com/v1beta/models/gemini-2.5-flash-lite:generateContent "HTTP/1.1 200 OK"
_trace.py:87 DEBUG: receive_response_body.started request=<Request [b'POST']>
_trace.py:87 DEBUG: receive_response_body.complete
_trace.py:87 DEBUG: response_closed.started
_trace.py:87 DEBUG: response_closed.complete
google_llm.py:186 INFO: Response received from the model.
types.py:6324 WARNING: Warning: there are non-text parts in the response: ['function_call'], returning concatenated text result from text parts. Check the full candidates.content.parts accessor to get the full model response.
google_llm.py:187 DEBUG: 
LLM Response:
-----------------------------------------------------------
Text:
None
-----------------------------------------------------------
Function calls:
name: google_search_agent, args: {'request': 'research papers on alopecia areata'}
-----------------------------------------------------------
Raw response:
{"sdk_http_response":{"headers":{"content-type":"application/json; charset=UTF-8","vary":"Origin, X-Origin, Referer","content-encoding":"gzip","date":"Wed, 19 Nov 2025 11:39:24 GMT","server":"scaffolding on HTTPServer2","x-xss-protection":"0","x-frame-options":"SAMEORIGIN","x-content-type-options":"nosniff","server-timing":"gfet4t7; dur=1031","alt-svc":"h3=\":443\"; ma=2592000,h3-29=\":443\"; ma=2592000","transfer-encoding":"chunked"}},"candidates":[{"content":{"parts":[{"function_call":{"args":{"request":"research papers on alopecia areata"},"name":"google_search_agent"}}],"role":"model"},"finish_reason":"STOP","index":0}],"model_version":"gemini-2.5-flash-lite","response_id":"bKwdaYPfLIPOnsEP9aWA-AY","usage_metadata":{"candidates_token_count":22,"prompt_token_count":225,"prompt_tokens_details":[{"modality":"TEXT","token_count":225}],"total_token_count":247}}
-----------------------------------------------------------

runners.py:266 WARNING: App name mismatch detected. The runner is configured with app name "InMemoryRunner", but the root agent was loaded from "D:\Google Course\myenv\Lib\site-packages\google\adk\agents", which implies app name "agents".
google_llm.py:133 INFO: Sending out request, model: gemini-2.5-flash-lite, backend: GoogleLLMVariant.GEMINI_API, stream: False
google_llm.py:139 DEBUG: 
LLM Request:
-----------------------------------------------------------
System Instruction:
Use the google_search tool to find information on the given topic. Return the raw search results.
    If the user asks for a list of papers, then give them the list of research papers you found and not the summary.

You are an agent. Your internal name is "google_search_agent".
-----------------------------------------------------------
Config:
{}
-----------------------------------------------------------
Contents:
{"parts":[{"text":"research papers on alopecia areata"}],"role":"user"}
-----------------------------------------------------------
Functions:

-----------------------------------------------------------

models.py:6856 INFO: AFC is enabled with max remote calls: 10.
_trace.py:87 DEBUG: connect_tcp.started host='generativelanguage.googleapis.com' port=443 local_address=None timeout=None socket_options=None
_trace.py:87 DEBUG: connect_tcp.complete return_value=<httpcore._backends.anyio.AnyIOStream object at 0x0000022B3CC3BC50>
_trace.py:87 DEBUG: start_tls.started ssl_context=<ssl.SSLContext object at 0x0000022B3C97AF70> server_hostname='generativelanguage.googleapis.com' timeout=None
_trace.py:87 DEBUG: start_tls.complete return_value=<httpcore._backends.anyio.AnyIOStream object at 0x0000022B3CBE90F0>
_trace.py:87 DEBUG: send_request_headers.started request=<Request [b'POST']>
_trace.py:87 DEBUG: send_request_headers.complete
_trace.py:87 DEBUG: send_request_body.started request=<Request [b'POST']>
_trace.py:87 DEBUG: send_request_body.complete
_trace.py:87 DEBUG: receive_response_headers.started request=<Request [b'POST']>
_trace.py:87 DEBUG: receive_response_headers.complete return_value=(b'HTTP/1.1', 200, b'OK', [(b'Content-Type', b'application/json; charset=UTF-8'), (b'Vary', b'Origin'), (b'Vary', b'X-Origin'), (b'Vary', b'Referer'), (b'Content-Encoding', b'gzip'), (b'Date', b'Wed, 19 Nov 2025 11:39:33 GMT'), (b'Server', b'scaffolding on HTTPServer2'), (b'X-XSS-Protection', b'0'), (b'X-Frame-Options', b'SAMEORIGIN'), (b'X-Content-Type-Options', b'nosniff'), (b'Server-Timing', b'gfet4t7; dur=7236'), (b'Alt-Svc', b'h3=":443"; ma=2592000,h3-29=":443"; ma=2592000'), (b'Transfer-Encoding', b'chunked')])
_client.py:1740 INFO: HTTP Request: POST https://generativelanguage.googleapis.com/v1beta/models/gemini-2.5-flash-lite:generateContent "HTTP/1.1 200 OK"
_trace.py:87 DEBUG: receive_response_body.started request=<Request [b'POST']>
_trace.py:87 DEBUG: receive_response_body.complete
_trace.py:87 DEBUG: response_closed.started
_trace.py:87 DEBUG: response_closed.complete
google_llm.py:186 INFO: Response received from the model.
google_llm.py:187 DEBUG: 
LLM Response:
-----------------------------------------------------------
Text:
Here is a summary of research papers on alopecia areata:

Alopecia areata (AA) is a complex autoimmune condition characterized by non-scarring hair loss, affecting hair follicles and nails. It typically presents as round patches of hair loss but can progress to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis). AA can occur at any age and is a recurrent condition with unpredictable course and frequent relapses. While not life-threatening, AA can have significant psychological and social impacts on affected individuals and their families.

**Pathogenesis:**
The exact cause of AA is not fully understood, but evidence suggests it is an autoimmune reaction against hair follicles, influenced by both genetic and environmental factors. The immune system mistakenly attacks hair follicles, which are normally protected from immune surveillance. Psychological stress has also been linked to the initiation and exacerbation of AA, with mast cells acting as a link between immune responses and stress.

**Epidemiology:**
AA is the second most common non-scarring alopecia after androgenic alopecia. Prevalence estimates in Americans range from 0.1% to 0.2%, with a lifetime incidence of 1.7% to 2.1%. It affects all genders and can occur at any age, though a significant percentage of cases appear before age 21 or after age 40.

**Current Treatments and Emerging Therapies:**
Treatment for AA is primarily aimed at halting disease activity, as there is no definitive cure. Treatment modalities are chosen based on the extent of hair loss and the patient's age.

*   **Traditional Treatments:** These include topical treatments like corticosteroids, prostaglandin analogs, minoxidil, and contact immunotherapy. Intralesional corticosteroid injections have shown better responses than topical steroids. Systemic steroids are used for more severe cases. However, many traditional treatments have limited efficacy, especially in extensive hair loss cases, and can have side effects.
*   **Janus Kinase (JAK) Inhibitors:** These represent a significant advancement in AA treatment. Baricitinib was the first JAK inhibitor approved by the FDA in 2022 for severe AA. Other JAK inhibitors like tofacitinib and ruxolitinib have also shown impressive results, with significant regrowth in a substantial percentage of patients. Research is ongoing into topical JAK inhibitors as a potentially safer alternative with fewer systemic side effects.
*   **Platelet-Rich Plasma (PRP):** PRP has shown promising results in improving hair regrowth compared to placebo in some studies, though its efficacy can be variable.
*   **Novel Approaches:** A new microneedle patch technology is being developed to deliver drugs that rebalance the immune response at the site of hair follicles, potentially halting the autoimmune attack and promoting hair regrowth while minimizing systemic side effects. This approach may also be applicable to other autoimmune skin diseases.

**Research Trends:**
Research into AA treatment has increased substantially over the last two decades, with a growing focus on emerging therapies such as JAK inhibitors and PRP. Clinical trials are crucial for evaluating the safety and efficacy of new treatments, and ongoing research aims to develop more targeted and effective therapies for AA.

**Key Research Papers:**

*   "Alopecia areata: a review of disease pathogenesis"
*   "Alopecia Areata: Review of Epidemiology, Pathophysiology, Current Treatments and Nanoparticulate Delivery System"
*   "Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options"
*   "An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options"
*   "Alopecia Research: What New Treatments Are on the Horizon?"
*   "How New Clinical Research Is Changing the Future of Alopecia Areata Treatment"
*   "Insights into Alopecia Areata: A Systematic Review of Prevalence, Pathogenesis, and Psychological Consequences"
*   "New treatment could reverse hair loss caused by an autoimmune skin disease"
*   "Recent Advances in Treatment of Alopecia Areata"
*   "Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review"
*   "Alopecia Areata: An Updated Review for 2023"
*   "A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes"
-----------------------------------------------------------
Function calls:

-----------------------------------------------------------
Raw response:
{"sdk_http_response":{"headers":{"content-type":"application/json; charset=UTF-8","vary":"Origin, X-Origin, Referer","content-encoding":"gzip","date":"Wed, 19 Nov 2025 11:39:33 GMT","server":"scaffolding on HTTPServer2","x-xss-protection":"0","x-frame-options":"SAMEORIGIN","x-content-type-options":"nosniff","server-timing":"gfet4t7; dur=7236","alt-svc":"h3=\":443\"; ma=2592000,h3-29=\":443\"; ma=2592000","transfer-encoding":"chunked"}},"candidates":[{"content":{"parts":[{"text":"Here is a summary of research papers on alopecia areata:\n\nAlopecia areata (AA) is a complex autoimmune condition characterized by non-scarring hair loss, affecting hair follicles and nails. It typically presents as round patches of hair loss but can progress to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis). AA can occur at any age and is a recurrent condition with unpredictable course and frequent relapses. While not life-threatening, AA can have significant psychological and social impacts on affected individuals and their families.\n\n**Pathogenesis:**\nThe exact cause of AA is not fully understood, but evidence suggests it is an autoimmune reaction against hair follicles, influenced by both genetic and environmental factors. The immune system mistakenly attacks hair follicles, which are normally protected from immune surveillance. Psychological stress has also been linked to the initiation and exacerbation of AA, with mast cells acting as a link between immune responses and stress.\n\n**Epidemiology:**\nAA is the second most common non-scarring alopecia after androgenic alopecia. Prevalence estimates in Americans range from 0.1% to 0.2%, with a lifetime incidence of 1.7% to 2.1%. It affects all genders and can occur at any age, though a significant percentage of cases appear before age 21 or after age 40.\n\n**Current Treatments and Emerging Therapies:**\nTreatment for AA is primarily aimed at halting disease activity, as there is no definitive cure. Treatment modalities are chosen based on the extent of hair loss and the patient's age.\n\n*   **Traditional Treatments:** These include topical treatments like corticosteroids, prostaglandin analogs, minoxidil, and contact immunotherapy. Intralesional corticosteroid injections have shown better responses than topical steroids. Systemic steroids are used for more severe cases. However, many traditional treatments have limited efficacy, especially in extensive hair loss cases, and can have side effects.\n*   **Janus Kinase (JAK) Inhibitors:** These represent a significant advancement in AA treatment. Baricitinib was the first JAK inhibitor approved by the FDA in 2022 for severe AA. Other JAK inhibitors like tofacitinib and ruxolitinib have also shown impressive results, with significant regrowth in a substantial percentage of patients. Research is ongoing into topical JAK inhibitors as a potentially safer alternative with fewer systemic side effects.\n*   **Platelet-Rich Plasma (PRP):** PRP has shown promising results in improving hair regrowth compared to placebo in some studies, though its efficacy can be variable.\n*   **Novel Approaches:** A new microneedle patch technology is being developed to deliver drugs that rebalance the immune response at the site of hair follicles, potentially halting the autoimmune attack and promoting hair regrowth while minimizing systemic side effects. This approach may also be applicable to other autoimmune skin diseases.\n\n**Research Trends:**\nResearch into AA treatment has increased substantially over the last two decades, with a growing focus on emerging therapies such as JAK inhibitors and PRP. Clinical trials are crucial for evaluating the safety and efficacy of new treatments, and ongoing research aims to develop more targeted and effective therapies for AA.\n\n**Key Research Papers:**\n\n*   \"Alopecia areata: a review of disease pathogenesis\"\n*   \"Alopecia Areata: Review of Epidemiology, Pathophysiology, Current Treatments and Nanoparticulate Delivery System\"\n*   \"Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options\"\n*   \"An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options\"\n*   \"Alopecia Research: What New Treatments Are on the Horizon?\"\n*   \"How New Clinical Research Is Changing the Future of Alopecia Areata Treatment\"\n*   \"Insights into Alopecia Areata: A Systematic Review of Prevalence, Pathogenesis, and Psychological Consequences\"\n*   \"New treatment could reverse hair loss caused by an autoimmune skin disease\"\n*   \"Recent Advances in Treatment of Alopecia Areata\"\n*   \"Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review\"\n*   \"Alopecia Areata: An Updated Review for 2023\"\n*   \"A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes\""}],"role":"model"},"finish_reason":"STOP","grounding_metadata":{"grounding_chunks":[{"web":{"title":"tandfonline.com","uri":"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFHX1be3R3n48WUstAfee1b8Pr4MxgkO8Oaw0Six0C93R-G4ccri1spLOcneE_91ieuMb0Mgt_pRqWp_ZMJE144oFJSDx5kHer7OfZ4CwSYCX648bjuV2llHvAjAVbdxW22EfsvP5UK4MLqI-GArnV4Mf-F7Q=="}},{"web":{"title":"miami.edu","uri":"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE_QfKlm3F-6fJBHlETM-RhS-60AYYFc6h31nA5gzNKS3KZ8EYG7nHZFgTtDX12iYHecEJhGjgf5xUEnuOsqYvUmCStGG72gLEW5qBW_mwtp15M_seuqBDSfpFaTD-36bPPFyHHrrJftH7iwKKE5w0Id1lXMw054vcIb5HbTLjbrRKumB59ZfpYcEfRgEU52nxGCftLYVMRIodABT052RxOhKCfXwUDdvaPQcKVFJbJI_kF-XQCVyRNcw=="}},{"web":{"title":"nih.gov","uri":"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEZNAonOWkPFcKBa1_khA7MfXTGhNOmXWeAckEuZ1frIbU8C-y6YUjF2KJyeRlUTwzTb6pbwyQWKZjNk83RQ9mW-ECUYZDum2WG6MjQyqHK11RFx-HrJm-pe5XMfY1GlulwbuQstrhlg_7clw=="}},{"web":{"title":"opendermatologyjournal.com","uri":"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF2qxCf5wq5KToAPD0_OLyX3gvnEgNOlueuvyEVCG1SqiVExwGWvauZosbOzf-ejsn_wqdeJZQkFT0VAlvEVzpYJp_8xtNnwMk-2ERLJ_H6PbNtG2QZtJt0eU6TQ9nVQqpaPbC-oGC1PFRCO7S9CrGotZcvcRKTewwyfKdVD0n-cQ=="}},{"web":{"title":"oup.com","uri":"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF0-6XY3lfFNwm1nwmx7j1vzKVI3qAmBsUVCRhJcMk7HHFYjIcs5Ic3eFq2LUBjgP3gdUsfER0a_6BoTxRe20ij2UG7QvBxZSNhhT8IfACG8zV7ujX9N_F-_VsnmLp_hFwB_sw9HmK_DSMsGLfhx1sewQ=="}},{"web":{"title":"ajmc.com","uri":"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGQZnzSkEyRvDZ3iAeilqdXXaC_xc8AOWFQoszVribvoDaDR-QNP1HYy1dYmenQBQFcA9BOzJ_G5ZE8QLuTlhUKDU8d1cZUwdDt-HV2_e1XxCshulleC0y6unaw7K9RnvAizMkrCDztYn1xJIMlJo7aV84b1x-60tiqo0rt4uaq9dKpp7xHrjdVhhO-dhYb"}},{"web":{"title":"nih.gov","uri":"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGtp_rjW3eTU6GIwV6XnM3hC--UH5g38YHubc3g368Uy-NqLQCMLVAEweWj7eMaq4zEbt29p3aC23CPZkwsDQXV4XdB3eJGJ3lXP-2pkA1Ywo744Q_wTbIsqinbDCh-d80MiqvyU2sgPmAmWRw="}},{"web":{"title":"researchgate.net","uri":"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEVaEAi2L8ZzDo2Nti5VI9IJj7lpDkeNfcLsdHq5BBHW-U05YVVdMllofy5kTv7CXZQLFgWT_KO7Ag5yV-bRr7eLJd6InGSPriIjp8Iq-hJzzhv3sa9mu1ZmUSyeYOe3BZPHwLTtk6ZD3VRAjdSsnTRZbewGVQOBlTEHeiDD61yCOz-Yf7SrRKGP_8b2KwU69_HqrLk_JKTEbODFrPilN3AkvE6uNFpmlpyBPudFXTUOZ5ReDKggLYuosb7yCw="}},{"web":{"title":"nih.gov","uri":"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE_LRJu2gJ8A1YKJLh7whp-hXpiAUPJfbHMi8oiqlBlGYmc96ij3nx7Ucs5p1TwwxgvTA7-CLxu1pXf_WmXJA7hHGt7g7l0LIYSfv2cGHi8iiJJpQtIOYywXQjZiSkhks38XPF0MBhua0Apq6o="}},{"web":{"title":"london-dermatology-centre.co.uk","uri":"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHAku3zirPaetxsHpBkQgHzEB8SrYAkSckEjW_70uta5SSyVADHsrlH9UueJiJFhm-FjDMFz_hGKJJEtGAQ4UPsbSGWsmTZefalbCW0HsuudlRgipmPrPJ0dW4PlWhn6tkUNUS4idhymNdX3hNkZc_e2lOldppSfh2ieTFNCdcPEONQ3126LQ=="}},{"web":{"title":"hcplive.com","uri":"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHuiGN_-6KKA0x04VuDwoQwlNYxmWx_3SmeBSjuSLTwY-HAv8VSGcVlfmLffxSR0VPjaCDJqJaBz2TNsIQ8tP-3v_JhhxnsqYL8RyqyQOWADSLhQmW0tMijpRvSKDsgtjfUiYBT73XLkQQwAQdHsOUaxl3y285qOZuva9WnC4c8Ia9e1fcLIRCvdx_So7eMww=="}},{"web":{"title":"mit.edu","uri":"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGbzhayxJvhUogQF7t5DgJ-PAxucKulJAaPSu_BqhoVmTjWSVOLgfd-fZKbD8-uW05HnsyyKegx7PAnUWmWrb6Nn9hxLuro2leMOvztfRvDmcddbVKCl1iqeta9T_l3eetaGx4IuXdhsS8Ty_Te9cJxNi8ofV1iTYAHEoh7DJduCsUwu5EF40y8RCzzaWVlGjO0sAtf0xGHHI2dwmKk"}},{"web":{"title":"sunresearch.com","uri":"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwCCk8Vy_e6INudB-7xO6cp9PEQiM2dustMPQ98jL9MuQgil4I8WcUxSfhq83K7u1RmOH5U_9XaPb-S_-QnST8uymceLKP9bDi6qT6NDrsH6ym27Kc5N-3PgCWOIWb9ieLa9OQA1DMoEAZpDOj03odNPE6sRQGEL3Kla5dMAqF1L_XnR7VSmSVyDAuukzSnQiWrKQGJXC9HOkszeOBOjeKz9UT3OFTGMc="}},{"web":{"title":"mdpi.com","uri":"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEhxSKMfpr0LRuWtpzcCC7M71jWKg8i_lO6ItYRaHtFRMFbM6hnNXWsJ9sIZ6ATcthvcHPFN8PBDa6kJC-gTDWT93-o_CkJCw7ONJhw8jzmso2sHfOKIt01dRenD-9ySlesdjs="}}],"grounding_supports":[{"grounding_chunk_indices":[0,1,2,3],"segment":{"end_index":189,"start_index":58,"text":"Alopecia areata (AA) is a complex autoimmune condition characterized by non-scarring hair loss, affecting hair follicles and nails."}},{"grounding_chunk_indices":[4,0,5],"segment":{"end_index":353,"start_index":190,"text":"It typically presents as round patches of hair loss but can progress to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis)."}},{"grounding_chunk_indices":[4,0,3],"segment":{"end_index":455,"start_index":354,"text":"AA can occur at any age and is a recurrent condition with unpredictable course and frequent relapses."}},{"grounding_chunk_indices":[0,3],"segment":{"end_index":584,"start_index":456,"text":"While not life-threatening, AA can have significant psychological and social impacts on affected individuals and their families."}},{"grounding_chunk_indices":[4,2,3],"segment":{"end_index":779,"start_index":586,"text":"**Pathogenesis:**\nThe exact cause of AA is not fully understood, but evidence suggests it is an autoimmune reaction against hair follicles, influenced by both genetic and environmental factors."}},{"grounding_chunk_indices":[4,2],"segment":{"end_index":887,"start_index":780,"text":"The immune system mistakenly attacks hair follicles, which are normally protected from immune surveillance."}},{"grounding_chunk_indices":[4],"segment":{"end_index":1041,"start_index":888,"text":"Psychological stress has also been linked to the initiation and exacerbation of AA, with mast cells acting as a link between immune responses and stress."}},{"grounding_chunk_indices":[0],"segment":{"end_index":1138,"start_index":1043,"text":"**Epidemiology:**\nAA is the second most common non-scarring alopecia after androgenic alopecia."}},{"grounding_chunk_indices":[0],"segment":{"end_index":1240,"start_index":1139,"text":"Prevalence estimates in Americans range from 0.1% to 0.2%, with a lifetime incidence of 1.7% to 2.1%."}},{"grounding_chunk_indices":[0],"segment":{"end_index":1368,"start_index":1241,"text":"It affects all genders and can occur at any age, though a significant percentage of cases appear before age 21 or after age 40."}},{"grounding_chunk_indices":[6],"segment":{"end_index":1513,"start_index":1370,"text":"**Current Treatments and Emerging Therapies:**\nTreatment for AA is primarily aimed at halting disease activity, as there is no definitive cure."}},{"grounding_chunk_indices":[6],"segment":{"end_index":1601,"start_index":1514,"text":"Treatment modalities are chosen based on the extent of hair loss and the patient's age."}},{"grounding_chunk_indices":[7],"segment":{"end_index":1750,"start_index":1603,"text":"*   **Traditional Treatments:** These include topical treatments like corticosteroids, prostaglandin analogs, minoxidil, and contact immunotherapy."}},{"grounding_chunk_indices":[8],"segment":{"end_index":1841,"start_index":1751,"text":"Intralesional corticosteroid injections have shown better responses than topical steroids."}},{"grounding_chunk_indices":[7,8],"segment":{"end_index":1891,"start_index":1842,"text":"Systemic steroids are used for more severe cases."}},{"grounding_chunk_indices":[0,6,8],"segment":{"end_index":2019,"start_index":1892,"text":"However, many traditional treatments have limited efficacy, especially in extensive hair loss cases, and can have side effects."}},{"grounding_chunk_indices":[5,9,10],"segment":{"end_index":2117,"start_index":2020,"text":"*   **Janus Kinase (JAK) Inhibitors:** These represent a significant advancement in AA treatment."}},{"grounding_chunk_indices":[9],"segment":{"end_index":2200,"start_index":2118,"text":"Baricitinib was the first JAK inhibitor approved by the FDA in 2022 for severe AA."}},{"grounding_chunk_indices":[9],"segment":{"end_index":2357,"start_index":2201,"text":"Other JAK inhibitors like tofacitinib and ruxolitinib have also shown impressive results, with significant regrowth in a substantial percentage of patients."}},{"grounding_chunk_indices":[9],"segment":{"end_index":2474,"start_index":2358,"text":"Research is ongoing into topical JAK inhibitors as a potentially safer alternative with fewer systemic side effects."}},{"grounding_chunk_indices":[2,5],"segment":{"end_index":2643,"start_index":2475,"text":"*   **Platelet-Rich Plasma (PRP):** PRP has shown promising results in improving hair regrowth compared to placebo in some studies, though its efficacy can be variable."}},{"grounding_chunk_indices":[11],"segment":{"end_index":2916,"start_index":2644,"text":"*   **Novel Approaches:** A new microneedle patch technology is being developed to deliver drugs that rebalance the immune response at the site of hair follicles, potentially halting the autoimmune attack and promoting hair regrowth while minimizing systemic side effects."}},{"grounding_chunk_indices":[11],"segment":{"end_index":2988,"start_index":2917,"text":"This approach may also be applicable to other autoimmune skin diseases."}},{"grounding_chunk_indices":[5],"segment":{"end_index":3167,"start_index":2990,"text":"**Research Trends:**\nResearch into AA treatment has increased substantially over the last two decades, with a growing focus on emerging therapies such as JAK inhibitors and PRP."}},{"grounding_chunk_indices":[12,11],"segment":{"end_index":3336,"start_index":3168,"text":"Clinical trials are crucial for evaluating the safety and efficacy of new treatments, and ongoing research aims to develop more targeted and effective therapies for AA."}},{"grounding_chunk_indices":[4],"segment":{"end_index":3419,"start_index":3364,"text":"*   \"Alopecia areata: a review of disease pathogenesis\""}},{"grounding_chunk_indices":[0],"segment":{"end_index":3538,"start_index":3420,"text":"*   \"Alopecia Areata: Review of Epidemiology, Pathophysiology, Current Treatments and Nanoparticulate Delivery System\""}},{"grounding_chunk_indices":[1,2],"segment":{"end_index":3644,"start_index":3539,"text":"*   \"Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options\""}},{"grounding_chunk_indices":[6],"segment":{"end_index":3738,"start_index":3645,"text":"*   \"An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options\""}},{"grounding_chunk_indices":[9],"segment":{"end_index":3803,"start_index":3739,"text":"*   \"Alopecia Research: What New Treatments Are on the Horizon?\""}},{"grounding_chunk_indices":[12],"segment":{"end_index":3887,"start_index":3804,"text":"*   \"How New Clinical Research Is Changing the Future of Alopecia Areata Treatment\""}},{"grounding_chunk_indices":[3],"segment":{"end_index":4004,"start_index":3888,"text":"*   \"Insights into Alopecia Areata: A Systematic Review of Prevalence, Pathogenesis, and Psychological Consequences\""}},{"grounding_chunk_indices":[11],"segment":{"end_index":4085,"start_index":4005,"text":"*   \"New treatment could reverse hair loss caused by an autoimmune skin disease\""}},{"grounding_chunk_indices":[10],"segment":{"end_index":4139,"start_index":4086,"text":"*   \"Recent Advances in Treatment of Alopecia Areata\""}},{"grounding_chunk_indices":[7],"segment":{"end_index":4226,"start_index":4140,"text":"*   \"Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review\""}},{"grounding_chunk_indices":[8],"segment":{"end_index":4276,"start_index":4227,"text":"*   \"Alopecia Areata: An Updated Review for 2023\""}},{"grounding_chunk_indices":[13],"segment":{"end_index":4426,"start_index":4277,"text":"*   \"A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes\""}}],"search_entry_point":{"rendered_content":"<style>\n.container {\n  align-items: center;\n  border-radius: 8px;\n  display: flex;\n  font-family: Google Sans, Roboto, sans-serif;\n  font-size: 14px;\n  line-height: 20px;\n  padding: 8px 12px;\n}\n.chip {\n  display: inline-block;\n  border: solid 1px;\n  border-radius: 16px;\n  min-width: 14px;\n  padding: 5px 16px;\n  text-align: center;\n  user-select: none;\n  margin: 0 8px;\n  -webkit-tap-highlight-color: transparent;\n}\n.carousel {\n  overflow: auto;\n  scrollbar-width: none;\n  white-space: nowrap;\n  margin-right: -12px;\n}\n.headline {\n  display: flex;\n  margin-right: 4px;\n}\n.gradient-container {\n  position: relative;\n}\n.gradient {\n  position: absolute;\n  transform: translate(3px, -9px);\n  height: 36px;\n  width: 9px;\n}\n@media (prefers-color-scheme: light) {\n  .container {\n    background-color: #fafafa;\n    box-shadow: 0 0 0 1px #0000000f;\n  }\n  .headline-label {\n    color: #1f1f1f;\n  }\n  .chip {\n    background-color: #ffffff;\n    border-color: #d2d2d2;\n    color: #5e5e5e;\n    text-decoration: none;\n  }\n  .chip:hover {\n    background-color: #f2f2f2;\n  }\n  .chip:focus {\n    background-color: #f2f2f2;\n  }\n  .chip:active {\n    background-color: #d8d8d8;\n    border-color: #b6b6b6;\n  }\n  .logo-dark {\n    display: none;\n  }\n  .gradient {\n    background: linear-gradient(90deg, #fafafa 15%, #fafafa00 100%);\n  }\n}\n@media (prefers-color-scheme: dark) {\n  .container {\n    background-color: #1f1f1f;\n    box-shadow: 0 0 0 1px #ffffff26;\n  }\n  .headline-label {\n    color: #fff;\n  }\n  .chip {\n    background-color: #2c2c2c;\n    border-color: #3c4043;\n    color: #fff;\n    text-decoration: none;\n  }\n  .chip:hover {\n    background-color: #353536;\n  }\n  .chip:focus {\n    background-color: #353536;\n  }\n  .chip:active {\n    background-color: #464849;\n    border-color: #53575b;\n  }\n  .logo-light {\n    display: none;\n  }\n  .gradient {\n    background: linear-gradient(90deg, #1f1f1f 15%, #1f1f1f00 100%);\n  }\n}\n</style>\n<div class=\"container\">\n  <div class=\"headline\">\n    <svg class=\"logo-light\" width=\"18\" height=\"18\" viewBox=\"9 9 35 35\" fill=\"none\" xmlns=\"http://www.w3.org/2000/svg\">\n      <path fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M42.8622 27.0064C42.8622 25.7839 42.7525 24.6084 42.5487 23.4799H26.3109V30.1568H35.5897C35.1821 32.3041 33.9596 34.1222 32.1258 35.3448V39.6864H37.7213C40.9814 36.677 42.8622 32.2571 42.8622 27.0064V27.0064Z\" fill=\"#4285F4\"/>\n      <path fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M26.3109 43.8555C30.9659 43.8555 34.8687 42.3195 37.7213 39.6863L32.1258 35.3447C30.5898 36.3792 28.6306 37.0061 26.3109 37.0061C21.8282 37.0061 18.0195 33.9811 16.6559 29.906H10.9194V34.3573C13.7563 39.9841 19.5712 43.8555 26.3109 43.8555V43.8555Z\" fill=\"#34A853\"/>\n      <path fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M16.6559 29.8904C16.3111 28.8559 16.1074 27.7588 16.1074 26.6146C16.1074 25.4704 16.3111 24.3733 16.6559 23.3388V18.8875H10.9194C9.74388 21.2072 9.06992 23.8247 9.06992 26.6146C9.06992 29.4045 9.74388 32.022 10.9194 34.3417L15.3864 30.8621L16.6559 29.8904V29.8904Z\" fill=\"#FBBC05\"/>\n      <path fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M26.3109 16.2386C28.85 16.2386 31.107 17.1164 32.9095 18.8091L37.8466 13.8719C34.853 11.082 30.9659 9.3736 26.3109 9.3736C19.5712 9.3736 13.7563 13.245 10.9194 18.8875L16.6559 23.3388C18.0195 19.2636 21.8282 16.2386 26.3109 16.2386V16.2386Z\" fill=\"#EA4335\"/>\n    </svg>\n    <svg class=\"logo-dark\" width=\"18\" height=\"18\" viewBox=\"0 0 48 48\" xmlns=\"http://www.w3.org/2000/svg\">\n      <circle cx=\"24\" cy=\"23\" fill=\"#FFF\" r=\"22\"/>\n      <path d=\"M33.76 34.26c2.75-2.56 4.49-6.37 4.49-11.26 0-.89-.08-1.84-.29-3H24.01v5.99h8.03c-.4 2.02-1.5 3.56-3.07 4.56v.75l3.91 2.97h.88z\" fill=\"#4285F4\"/>\n      <path d=\"M15.58 25.77A8.845 8.845 0 0 0 24 31.86c1.92 0 3.62-.46 4.97-1.31l4.79 3.71C31.14 36.7 27.65 38 24 38c-5.93 0-11.01-3.4-13.45-8.36l.17-1.01 4.06-2.85h.8z\" fill=\"#34A853\"/>\n      <path d=\"M15.59 20.21a8.864 8.864 0 0 0 0 5.58l-5.03 3.86c-.98-2-1.53-4.25-1.53-6.64 0-2.39.55-4.64 1.53-6.64l1-.22 3.81 2.98.22 1.08z\" fill=\"#FBBC05\"/>\n      <path d=\"M24 14.14c2.11 0 4.02.75 5.52 1.98l4.36-4.36C31.22 9.43 27.81 8 24 8c-5.93 0-11.01 3.4-13.45 8.36l5.03 3.85A8.86 8.86 0 0 1 24 14.14z\" fill=\"#EA4335\"/>\n    </svg>\n    <div class=\"gradient-container\"><div class=\"gradient\"></div></div>\n  </div>\n  <div class=\"carousel\">\n    <a class=\"chip\" href=\"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF1-RDe95F3ON3fVM0EzzCE7PKMqAuHy5Rao0KGQ64B8K8jFnsFXhSEnQv5g3D0GiezkLWFOLnfE6A7E3b8DW-ykGDdkskIxKIbGCtj3jj9fM8pNFYk8j8VOHckIsOn02pd5jcssEpCI0FiSl-kdmJt1-d4LZUc_n58xf1HyQ5iTGWO1TlX_3s-Q41gU5t3eztqWN885Fr2AvdrTI1uGOK4cg==\">alopecia areata research review</a>\n    <a class=\"chip\" href=\"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHbVXHzpq4vwTZLFYX97ajZqOTmMOBx7p5iuE4ZfVzoDnwxak2YL6Y8v326viET_S7bRRPhmSoOIgiJNSoCrcdatdG9_H5BbcOs8sawSC7iWqb2wMj-PfiK-fVL3Jrgs3n3OrvHlyaNdLfIOexpMmqVG5zQDeeBwvBmDyeGmwgJdjDjjU69gQK66QCg_SPxzIbte7non0qDNKUBLTFO64yo5anPTQ==\">research papers on alopecia areata</a>\n    <a class=\"chip\" href=\"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG_iL3lWc1zFJ1EnvpaILgF1SXnUwPZ7Appx8ZkeFlgH7bCEqM4Rk48rf7nnmSDAT1x7ZWcHN1uEpL1kRfI5h4DUWxiq6ww9nZjRvz8IM2YvwvZai5QeO_LjLVQH6Fs6iSeWRP_L9AHXgXLkcVfk2OYgvP9P1MqAxf-tpgfV5yZkBF9sdoxXen_TRFEsryRJZhqDJLAh7dyJVxHgXJJ68BphQTwK-VuVmAsdYMXjg==\">recent advances in alopecia areata research</a>\n  </div>\n</div>\n"},"web_search_queries":["research papers on alopecia areata","alopecia areata research review","recent advances in alopecia areata research"]},"index":0}],"model_version":"gemini-2.5-flash-lite","response_id":"dawdafqgJofxnsEPidOTqQM","usage_metadata":{"candidates_token_count":941,"prompt_token_count":72,"prompt_tokens_details":[{"modality":"TEXT","token_count":72}],"tool_use_prompt_token_count":106,"tool_use_prompt_tokens_details":[{"modality":"TEXT","token_count":106}],"total_token_count":1119},"automatic_function_calling_history":[]}
-----------------------------------------------------------

google_llm.py:133 INFO: Sending out request, model: gemini-2.5-flash-lite, backend: GoogleLLMVariant.GEMINI_API, stream: False
google_llm.py:139 DEBUG: 
LLM Request:
-----------------------------------------------------------
System Instruction:
Your task is to find research papers and count them. 

    You MUST ALWAYS follow these steps:
    1) Find research papers on the user provided topic using the 'google_search_agent'. 
    2) Then, pass the papers to 'count_papers' tool to count the number of papers returned.
    3) Return both the list of research papers and the total number of papers.

You are an agent. Your internal name is "root_agent".
-----------------------------------------------------------
Config:
{'tools': [{}]}
-----------------------------------------------------------
Contents:
{"parts":[{"text":"what are the research on alopecia areta?"}],"role":"user"}
{"parts":[{"function_call":{"args":{"request":"research papers on alopecia areata"},"name":"google_search_agent"}}],"role":"model"}
{"parts":[{"function_response":{"name":"google_search_agent","response":{"result":"Here is a summary of research papers on alopecia areata:\n\nAlopecia areata (AA) is a complex autoimmune condition characterized by non-scarring hair loss, affecting hair follicles and nails. It typically presents as round patches of hair loss but can progress to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis). AA can occur at any age and is a recurrent condition with unpredictable course and frequent relapses. While not life-threatening, AA can have significant psychological and social impacts on affected individuals and their families.\n\n**Pathogenesis:**\nThe exact cause of AA is not fully understood, but evidence suggests it is an autoimmune reaction against hair follicles, influenced by both genetic and environmental factors. The immune system mistakenly attacks hair follicles, which are normally protected from immune surveillance. Psychological stress has also been linked to the initiation and exacerbation of AA, with mast cells acting as a link between immune responses and stress.\n\n**Epidemiology:**\nAA is the second most common non-scarring alopecia after androgenic alopecia. Prevalence estimates in Americans range from 0.1% to 0.2%, with a lifetime incidence of 1.7% to 2.1%. It affects all genders and can occur at any age, though a significant percentage of cases appear before age 21 or after age 40.\n\n**Current Treatments and Emerging Therapies:**\nTreatment for AA is primarily aimed at halting disease activity, as there is no definitive cure. Treatment modalities are chosen based on the extent of hair loss and the patient's age.\n\n*   **Traditional Treatments:** These include topical treatments like corticosteroids, prostaglandin analogs, minoxidil, and contact immunotherapy. Intralesional corticosteroid injections have shown better responses than topical steroids. Systemic steroids are used for more severe cases. However, many traditional treatments have limited efficacy, especially in extensive hair loss cases, and can have side effects.\n*   **Janus Kinase (JAK) Inhibitors:** These represent a significant advancement in AA treatment. Baricitinib was the first JAK inhibitor approved by the FDA in 2022 for severe AA. Other JAK inhibitors like tofacitinib and ruxolitinib have also shown impressive results, with significant regrowth in a substantial percentage of patients. Research is ongoing into topical JAK inhibitors as a potentially safer alternative with fewer systemic side effects.\n*   **Platelet-Rich Plasma (PRP):** PRP has shown promising results in improving hair regrowth compared to placebo in some studies, though its efficacy can be variable.\n*   **Novel Approaches:** A new microneedle patch technology is being developed to deliver drugs that rebalance the immune response at the site of hair follicles, potentially halting the autoimmune attack and promoting hair regrowth while minimizing systemic side effects. This approach may also be applicable to other autoimmune skin diseases.\n\n**Research Trends:**\nResearch into AA treatment has increased substantially over the last two decades, with a growing focus on emerging therapies such as JAK inhibitors and PRP. Clinical trials are crucial for evaluating the safety and efficacy of new treatments, and ongoing research aims to develop more targeted and effective therapies for AA.\n\n**Key Research Papers:**\n\n*   \"Alopecia areata: a review of disease pathogenesis\"\n*   \"Alopecia Areata: Review of Epidemiology, Pathophysiology, Current Treatments and Nanoparticulate Delivery System\"\n*   \"Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options\"\n*   \"An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options\"\n*   \"Alopecia Research: What New Treatments Are on the Horizon?\"\n*   \"How New Clinical Research Is Changing the Future of Alopecia Areata Treatment\"\n*   \"Insights into Alopecia Areata: A Systematic Review of Prevalence, Pathogenesis, and Psychological Consequences\"\n*   \"New treatment could reverse hair loss caused by an autoimmune skin disease\"\n*   \"Recent Advances in Treatment of Alopecia Areata\"\n*   \"Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review\"\n*   \"Alopecia Areata: An Updated Review for 2023\"\n*   \"A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes\""}}}],"role":"user"}
-----------------------------------------------------------
Functions:
paper_count: {'papers': {'type': <Type.STRING: 'STRING'>}} 
google_search_agent: {'request': {'type': <Type.STRING: 'STRING'>}} 
-----------------------------------------------------------

_trace.py:87 DEBUG: close.started
_trace.py:87 DEBUG: close.complete
_trace.py:87 DEBUG: connect_tcp.started host='generativelanguage.googleapis.com' port=443 local_address=None timeout=None socket_options=None
_trace.py:87 DEBUG: connect_tcp.complete return_value=<httpcore._backends.anyio.AnyIOStream object at 0x0000022B3CBE95B0>
_trace.py:87 DEBUG: start_tls.started ssl_context=<ssl.SSLContext object at 0x0000022B3C7BF4A0> server_hostname='generativelanguage.googleapis.com' timeout=None
_trace.py:87 DEBUG: start_tls.complete return_value=<httpcore._backends.anyio.AnyIOStream object at 0x0000022B3CBC2450>
_trace.py:87 DEBUG: send_request_headers.started request=<Request [b'POST']>
_trace.py:87 DEBUG: send_request_headers.complete
_trace.py:87 DEBUG: send_request_body.started request=<Request [b'POST']>
_trace.py:87 DEBUG: send_request_body.complete
_trace.py:87 DEBUG: receive_response_headers.started request=<Request [b'POST']>
_trace.py:87 DEBUG: receive_response_headers.complete return_value=(b'HTTP/1.1', 200, b'OK', [(b'Content-Type', b'application/json; charset=UTF-8'), (b'Vary', b'Origin'), (b'Vary', b'X-Origin'), (b'Vary', b'Referer'), (b'Content-Encoding', b'gzip'), (b'Date', b'Wed, 19 Nov 2025 11:39:35 GMT'), (b'Server', b'scaffolding on HTTPServer2'), (b'X-XSS-Protection', b'0'), (b'X-Frame-Options', b'SAMEORIGIN'), (b'X-Content-Type-Options', b'nosniff'), (b'Server-Timing', b'gfet4t7; dur=1393'), (b'Alt-Svc', b'h3=":443"; ma=2592000,h3-29=":443"; ma=2592000'), (b'Transfer-Encoding', b'chunked')])
_client.py:1740 INFO: HTTP Request: POST https://generativelanguage.googleapis.com/v1beta/models/gemini-2.5-flash-lite:generateContent "HTTP/1.1 200 OK"
_trace.py:87 DEBUG: receive_response_body.started request=<Request [b'POST']>
_trace.py:87 DEBUG: receive_response_body.complete
_trace.py:87 DEBUG: response_closed.started
_trace.py:87 DEBUG: response_closed.complete
google_llm.py:186 INFO: Response received from the model.
types.py:6324 WARNING: Warning: there are non-text parts in the response: ['function_call'], returning concatenated text result from text parts. Check the full candidates.content.parts accessor to get the full model response.
google_llm.py:187 DEBUG: 
LLM Response:
-----------------------------------------------------------
Text:
None
-----------------------------------------------------------
Function calls:
name: paper_count, args: {'papers': '["Alopecia areata: a review of disease pathogenesis", "Alopecia Areata: Review of Epidemiology, Pathophysiology, Current Treatments and Nanoparticulate Delivery System", "Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options", "An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options", "Alopecia Research: What New Treatments Are on the Horizon?", "How New Clinical Research Is Changing the Future of Alopecia Areata Treatment", "Insights into Alopecia Areata: A Systematic Review of Prevalence, Pathogenesis, and Psychological Consequences", "New treatment could reverse hair loss caused by an autoimmune skin disease", "Recent Advances in Treatment of Alopecia Areata", "Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review", "Alopecia Areata: An Updated Review for 2023", "A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes"]'}
-----------------------------------------------------------
Raw response:
{"sdk_http_response":{"headers":{"content-type":"application/json; charset=UTF-8","vary":"Origin, X-Origin, Referer","content-encoding":"gzip","date":"Wed, 19 Nov 2025 11:39:35 GMT","server":"scaffolding on HTTPServer2","x-xss-protection":"0","x-frame-options":"SAMEORIGIN","x-content-type-options":"nosniff","server-timing":"gfet4t7; dur=1393","alt-svc":"h3=\":443\"; ma=2592000,h3-29=\":443\"; ma=2592000","transfer-encoding":"chunked"}},"candidates":[{"content":{"parts":[{"function_call":{"args":{"papers":"[\"Alopecia areata: a review of disease pathogenesis\", \"Alopecia Areata: Review of Epidemiology, Pathophysiology, Current Treatments and Nanoparticulate Delivery System\", \"Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options\", \"An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options\", \"Alopecia Research: What New Treatments Are on the Horizon?\", \"How New Clinical Research Is Changing the Future of Alopecia Areata Treatment\", \"Insights into Alopecia Areata: A Systematic Review of Prevalence, Pathogenesis, and Psychological Consequences\", \"New treatment could reverse hair loss caused by an autoimmune skin disease\", \"Recent Advances in Treatment of Alopecia Areata\", \"Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review\", \"Alopecia Areata: An Updated Review for 2023\", \"A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes\"]"},"name":"paper_count"}}],"role":"model"},"finish_reason":"STOP","index":0}],"model_version":"gemini-2.5-flash-lite","response_id":"d6wdaf2TNJfMkdUP0o7A8QI","usage_metadata":{"candidates_token_count":232,"prompt_token_count":1191,"prompt_tokens_details":[{"modality":"TEXT","token_count":1191}],"total_token_count":1423}}
-----------------------------------------------------------

google_llm.py:133 INFO: Sending out request, model: gemini-2.5-flash-lite, backend: GoogleLLMVariant.GEMINI_API, stream: False
google_llm.py:139 DEBUG: 
LLM Request:
-----------------------------------------------------------
System Instruction:
Your task is to find research papers and count them. 

    You MUST ALWAYS follow these steps:
    1) Find research papers on the user provided topic using the 'google_search_agent'. 
    2) Then, pass the papers to 'count_papers' tool to count the number of papers returned.
    3) Return both the list of research papers and the total number of papers.

You are an agent. Your internal name is "root_agent".
-----------------------------------------------------------
Config:
{'tools': [{}]}
-----------------------------------------------------------
Contents:
{"parts":[{"text":"what are the research on alopecia areta?"}],"role":"user"}
{"parts":[{"function_call":{"args":{"request":"research papers on alopecia areata"},"name":"google_search_agent"}}],"role":"model"}
{"parts":[{"function_response":{"name":"google_search_agent","response":{"result":"Here is a summary of research papers on alopecia areata:\n\nAlopecia areata (AA) is a complex autoimmune condition characterized by non-scarring hair loss, affecting hair follicles and nails. It typically presents as round patches of hair loss but can progress to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis). AA can occur at any age and is a recurrent condition with unpredictable course and frequent relapses. While not life-threatening, AA can have significant psychological and social impacts on affected individuals and their families.\n\n**Pathogenesis:**\nThe exact cause of AA is not fully understood, but evidence suggests it is an autoimmune reaction against hair follicles, influenced by both genetic and environmental factors. The immune system mistakenly attacks hair follicles, which are normally protected from immune surveillance. Psychological stress has also been linked to the initiation and exacerbation of AA, with mast cells acting as a link between immune responses and stress.\n\n**Epidemiology:**\nAA is the second most common non-scarring alopecia after androgenic alopecia. Prevalence estimates in Americans range from 0.1% to 0.2%, with a lifetime incidence of 1.7% to 2.1%. It affects all genders and can occur at any age, though a significant percentage of cases appear before age 21 or after age 40.\n\n**Current Treatments and Emerging Therapies:**\nTreatment for AA is primarily aimed at halting disease activity, as there is no definitive cure. Treatment modalities are chosen based on the extent of hair loss and the patient's age.\n\n*   **Traditional Treatments:** These include topical treatments like corticosteroids, prostaglandin analogs, minoxidil, and contact immunotherapy. Intralesional corticosteroid injections have shown better responses than topical steroids. Systemic steroids are used for more severe cases. However, many traditional treatments have limited efficacy, especially in extensive hair loss cases, and can have side effects.\n*   **Janus Kinase (JAK) Inhibitors:** These represent a significant advancement in AA treatment. Baricitinib was the first JAK inhibitor approved by the FDA in 2022 for severe AA. Other JAK inhibitors like tofacitinib and ruxolitinib have also shown impressive results, with significant regrowth in a substantial percentage of patients. Research is ongoing into topical JAK inhibitors as a potentially safer alternative with fewer systemic side effects.\n*   **Platelet-Rich Plasma (PRP):** PRP has shown promising results in improving hair regrowth compared to placebo in some studies, though its efficacy can be variable.\n*   **Novel Approaches:** A new microneedle patch technology is being developed to deliver drugs that rebalance the immune response at the site of hair follicles, potentially halting the autoimmune attack and promoting hair regrowth while minimizing systemic side effects. This approach may also be applicable to other autoimmune skin diseases.\n\n**Research Trends:**\nResearch into AA treatment has increased substantially over the last two decades, with a growing focus on emerging therapies such as JAK inhibitors and PRP. Clinical trials are crucial for evaluating the safety and efficacy of new treatments, and ongoing research aims to develop more targeted and effective therapies for AA.\n\n**Key Research Papers:**\n\n*   \"Alopecia areata: a review of disease pathogenesis\"\n*   \"Alopecia Areata: Review of Epidemiology, Pathophysiology, Current Treatments and Nanoparticulate Delivery System\"\n*   \"Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options\"\n*   \"An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options\"\n*   \"Alopecia Research: What New Treatments Are on the Horizon?\"\n*   \"How New Clinical Research Is Changing the Future of Alopecia Areata Treatment\"\n*   \"Insights into Alopecia Areata: A Systematic Review of Prevalence, Pathogenesis, and Psychological Consequences\"\n*   \"New treatment could reverse hair loss caused by an autoimmune skin disease\"\n*   \"Recent Advances in Treatment of Alopecia Areata\"\n*   \"Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review\"\n*   \"Alopecia Areata: An Updated Review for 2023\"\n*   \"A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes\""}}}],"role":"user"}
{"parts":[{"function_call":{"args":{"papers":"[\"Alopecia areata: a review of disease pathogenesis\", \"Alopecia Areata: Review of Epidemiology, Pathophysiology, Current Treatments and Nanoparticulate Delivery System\", \"Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options\", \"An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options\", \"Alopecia Research: What New Treatments Are on the Horizon?\", \"How New Clinical Research Is Changing the Future of Alopecia Areata Treatment\", \"Insights into Alopecia Areata: A Systematic Review of Prevalence, Pathogenesis, and Psychological Consequences\", \"New treatment could reverse hair loss caused by an autoimmune skin disease\", \"Recent Advances in Treatment of Alopecia Areata\", \"Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review\", \"Alopecia Areata: An Updated Review for 2023\", \"A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes\"]"},"name":"paper_count"}}],"role":"model"}
{"parts":[{"function_response":{"name":"paper_count","response":{"result":1027}}}],"role":"user"}
-----------------------------------------------------------
Functions:
paper_count: {'papers': {'type': <Type.STRING: 'STRING'>}} 
google_search_agent: {'request': {'type': <Type.STRING: 'STRING'>}} 
-----------------------------------------------------------

_trace.py:87 DEBUG: send_request_headers.started request=<Request [b'POST']>
_trace.py:87 DEBUG: send_request_headers.complete
_trace.py:87 DEBUG: send_request_body.started request=<Request [b'POST']>
_trace.py:87 DEBUG: send_request_body.complete
_trace.py:87 DEBUG: receive_response_headers.started request=<Request [b'POST']>
_trace.py:87 DEBUG: receive_response_headers.complete return_value=(b'HTTP/1.1', 200, b'OK', [(b'Content-Type', b'application/json; charset=UTF-8'), (b'Vary', b'Origin'), (b'Vary', b'X-Origin'), (b'Vary', b'Referer'), (b'Content-Encoding', b'gzip'), (b'Date', b'Wed, 19 Nov 2025 11:39:37 GMT'), (b'Server', b'scaffolding on HTTPServer2'), (b'X-XSS-Protection', b'0'), (b'X-Frame-Options', b'SAMEORIGIN'), (b'X-Content-Type-Options', b'nosniff'), (b'Server-Timing', b'gfet4t7; dur=1371'), (b'Alt-Svc', b'h3=":443"; ma=2592000,h3-29=":443"; ma=2592000'), (b'Transfer-Encoding', b'chunked')])
_client.py:1740 INFO: HTTP Request: POST https://generativelanguage.googleapis.com/v1beta/models/gemini-2.5-flash-lite:generateContent "HTTP/1.1 200 OK"
_trace.py:87 DEBUG: receive_response_body.started request=<Request [b'POST']>
_trace.py:87 DEBUG: receive_response_body.complete
_trace.py:87 DEBUG: response_closed.started
_trace.py:87 DEBUG: response_closed.complete
google_llm.py:186 INFO: Response received from the model.
google_llm.py:187 DEBUG: 
LLM Response:
-----------------------------------------------------------
Text:
Here are some research papers on alopecia areata:

*   Alopecia areata: a review of disease pathogenesis
*   Alopecia Areata: Review of Epidemiology, Pathophysiology, Current Treatments and Nanoparticulate Delivery System
*   Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options
*   An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options
*   Alopecia Research: What New Treatments Are on the Horizon?
*   How New Clinical Research Is Changing the Future of Alopecia Areata Treatment
*   Insights into Alopecia Areata: A Systematic Review of Prevalence, Pathogenesis, and Psychological Consequences
*   New treatment could reverse hair loss caused by an autoimmune skin disease
*   Recent Advances in Treatment of Alopecia Areata
*   Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review
*   Alopecia Areata: An Updated Review for 2023
*   A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes

A total of 1027 research papers were found.
-----------------------------------------------------------
Function calls:

-----------------------------------------------------------
Raw response:
{"sdk_http_response":{"headers":{"content-type":"application/json; charset=UTF-8","vary":"Origin, X-Origin, Referer","content-encoding":"gzip","date":"Wed, 19 Nov 2025 11:39:37 GMT","server":"scaffolding on HTTPServer2","x-xss-protection":"0","x-frame-options":"SAMEORIGIN","x-content-type-options":"nosniff","server-timing":"gfet4t7; dur=1371","alt-svc":"h3=\":443\"; ma=2592000,h3-29=\":443\"; ma=2592000","transfer-encoding":"chunked"}},"candidates":[{"content":{"parts":[{"text":"Here are some research papers on alopecia areata:\n\n*   Alopecia areata: a review of disease pathogenesis\n*   Alopecia Areata: Review of Epidemiology, Pathophysiology, Current Treatments and Nanoparticulate Delivery System\n*   Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options\n*   An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options\n*   Alopecia Research: What New Treatments Are on the Horizon?\n*   How New Clinical Research Is Changing the Future of Alopecia Areata Treatment\n*   Insights into Alopecia Areata: A Systematic Review of Prevalence, Pathogenesis, and Psychological Consequences\n*   New treatment could reverse hair loss caused by an autoimmune skin disease\n*   Recent Advances in Treatment of Alopecia Areata\n*   Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review\n*   Alopecia Areata: An Updated Review for 2023\n*   A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes\n\nA total of 1027 research papers were found."}],"role":"model"},"finish_reason":"STOP","index":0}],"model_version":"gemini-2.5-flash-lite","response_id":"eawdadmyFfG4kdUPtcqRwAY","usage_metadata":{"candidates_token_count":253,"prompt_token_count":1441,"prompt_tokens_details":[{"modality":"TEXT","token_count":1441}],"total_token_count":1694}}
-----------------------------------------------------------

runners.py:266 WARNING: App name mismatch detected. The runner is configured with app name "InMemoryRunner", but the root agent was loaded from "D:\Google Course\myenv\Lib\site-packages\google\adk\agents", which implies app name "agents".
